Cardiol Therapeutics Inc.

TSX:CRDL Stock Report

Market Cap: CA$209.6m

Cardiol Therapeutics Future Growth

Future criteria checks 0/6

Cardiol Therapeutics is forecast to grow earnings and revenue by 40.8% and 76.2% per annum respectively while EPS is expected to grow by 43% per annum.

Key information

40.8%

Earnings growth rate

43.0%

EPS growth rate

Pharmaceuticals earnings growth50.2%
Revenue growth rate76.2%
Future return on equityn/a
Analyst coverage

Low

Last updated11 Sep 2024

Recent future growth updates

Recent updates

We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Sep 12
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

May 01
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?

Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Jan 06
Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?

Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

Sep 13
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

May 24
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Jan 20
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

Aug 10
We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth

We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Apr 17
We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Dec 09
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Aug 19
We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Apr 18
Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation

Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Jan 03
Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth

Earnings and Revenue Growth Forecasts

TSX:CRDL - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20264-33-30-304
12/31/2025N/A-33-18-175
12/31/2024N/A-31-19-195
6/30/2024N/A-29-22-22N/A
3/31/2024N/A-30-22-22N/A
12/31/2023N/A-28-25-25N/A
9/30/2023N/A-28-31-31N/A
6/30/2023N/A-30-30-30N/A
3/31/2023N/A-29-27-27N/A
12/31/2022N/A-31-27-27N/A
9/30/2022N/A-30-19-19N/A
6/30/2022N/A-32-23-23N/A
3/31/20220-32-27-27N/A
12/31/20210-32-24-24N/A
9/30/20210-35-22-22N/A
6/30/20210-30-19-19N/A
3/31/2021N/A-27-14-14N/A
12/31/2020N/A-21-9-9N/A
9/30/2020N/A-14-10-10N/A
6/30/2020N/A-13-9-9N/A
3/31/2020N/A-13-10-10N/A
12/31/2019N/A-14-12-11N/A
9/30/2019N/A-20-17-17N/A
6/30/2019N/A-21-16-16N/A
3/31/2019N/A-19-15-15N/A
12/31/2018N/A-16-11-11N/A
9/30/2018N/A-8-3-3N/A
6/30/2018N/A-3-2-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRDL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRDL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRDL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRDL is forecast to have no revenue next year.

High Growth Revenue: CRDL is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CRDL's Return on Equity is forecast to be high in 3 years time


Discover growth companies